India, May 3 -- US-based ImmunityBio, Inc.has signed an exclusive global arrangement with the Serum Institute of India (SII), to supply ImmunityBio with Bacillus Calmette-Guerin (BCG). The agreement covers the manufacturing of standard BCG (sBCG) that is currently approved for use outside the US, as well as a next-generation recombinant BCG (iBCG) undergoing testing, intended for use in combination with ImmunityBio's ANKTIVA for currently approved and potential future indications, subject to regulatory approvals.

The arrangement will result in additional supplies of the current standard sBCG immediately for trials. At the same time, the two companies will work to accelerate the ongoing Phase 2 clinical trials of iBCG currently being cond...